Adaptive Biotechnologies (ADPT) vs CG Oncology (CGON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Adaptive Biotechnologies (ADPT) has outperformed CG Oncology (CGON) over the past year, gaining 83.1% versus a gain of 64.2%. CG Oncology is the larger company by market cap ($5.53 billion vs $4.19 billion), about 1.3 times the size. Adaptive Biotechnologies converts more of its revenue into profit, with a net margin of -21.5% versus -3985.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | CGON |
|---|---|---|
| Share price | $26.28 | $62.38 |
| Market cap | $4.19B | $5.53B |
| 1-day change | -2.30% | -1.98% |
| YTD return | +61.82% | +50.24% |
| 1-year return | +83.14% | +64.16% |
| 5-year return | -21.55% | — |
| EPS (TTM) | $-0.41 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $4.04M |
| Revenue growth (YoY) | +54.77% | +254.70% |
| Net income (latest FY) | $-59.50M | $-161.00M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | -4722.13% |
| Net margin | -21.48% | -3985.02% |
| 52-week high | $30.74 | $80.97 |
| 52-week low | $12.00 | $35.80 |
| Distance from 52-week high | -14.51% | -22.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +7.72% | +46.01% |
| Average volume | 2.39M | 899.28K |
| Shares outstanding | 159.60M | 88.64M |
| Employees | 624 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADPT has outperformed CGON by 19.0 percentage points over the past year.
- Adaptive Biotechnologies is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs +54.77%).
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
ADPT vs CGON FAQ
Which is bigger, Adaptive Biotechnologies or CG Oncology?
CG Oncology (CGON) is larger, with a market capitalization of $5.53B compared with $4.19B for Adaptive Biotechnologies (ADPT).
Which stock has performed better over the past year, ADPT or CGON?
ADPT returned +83.14% over the past 12 months, compared with +64.16% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and CG Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.